ABSTRACT
Chronic obstructive pulmonary disease (COPD) is a common respiratory disease, and lung cancer is a common comorbidity and one of the main causes of death in COPD. The coexistence of the two diseases is related to poor survival rate. Clinically, it has been found that COPD has a high comorbidity rate with lung cancer, belonging to a homologous disease with common risk factors and pathogenesis. COPD can be derived from the soil where lung cancer occurs. At present, there is much understanding of the association between COPD and the risk of lung cancer in clinical practice, but there is no consensus on the management of patients with COPD combined with lung cancer. There is insufficient diagnosis and treatment of COPD, which affects the clinical outcomes of such patients. Therefore, this article reviews the epidemiological status, common risk factors, related pathogenesis, and management of COPD combined with lung cancer in recent years, in order to provide more theoretical basis and understanding for clinical research and treatment.
ABSTRACT
Objective To evaluate the efficacy of Budesonide/formoterol to control asthma under real-life conditions.Methods A muhi-center, open label, non-interventional study was conducted.Asthma control after 12 week therapy with Budesonide/formoterol was assessed by Asthma Control Questionnaire (ACQ) and modified Asthma Control Questionnaire (ACQ5).Results A total of 360 asthma patients were recruited,including 228 adult patients and 132 child patients.After 12 weeks' therapy,all the patients' medium value of ACQ was decreased significantly from 2.03 (adults 2.20, children 1.74) at baseline to 0.60 (adults 0.78, children 0.29) (P < 0.0001), and the medium value of ACQ5 was also decreased significantly from 2.4 (adults 2.24, children 1.76) at baseline to 0.47 (adults 0.62, children 0.20) (P < 0.0001).Conclusion Budesonide/formoterol is effective in asthma treatment, by which most asthma patients obtain and maintain clineal control.